Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2025-12-29 @ 1:34 PM
Study NCT ID:
NCT06027268
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-17
First Post:
2023-08-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Sponsor:
Wake Forest University Health Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-10
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-31
First Submit QC Date:
None
Study First Post Date:
2023-09-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-14
Last Update Post Date:
2025-10-17
Last Update Post Date Type:
ESTIMATED